SCHEMBL20914357

SCHEMBL20914357

COC1CCCC(c2nnc(-c3c(C)[nH]c4c(-c5ccccc5)c(C(F)(F)F)nn4c3=O)o2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLAT P00750 4/20 0.38
▸ HSD11B1 P28845 1/20 0.32
▸ POLB P06746 3/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ ARF6 P62330 3/20 0.31
▸ HDAC3 O15379 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ HDAC1 Q13547 1/20 0.31
▸ HDAC6 Q9UBN7 1/20 0.31
▸ ALDH1A1 P00352 2/20 0.30
▸ L3MBTL1 Q9Y468 2/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ TLR9 Q9NR96 2/20 0.30
▸ TLR8 Q9NR97 2/20 0.30
▸ TLR7 Q9NYK1 2/20 0.30
▸ TNKS O95271 4/20 0.30
▸ PARP1 P09874 2/20 0.30
▸ PARP2 Q9UGN5 2/20 0.30
▸ NPC1 O15118 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914007 0.90 PLAT (0.43) PLATHSD11B1POLBKDM4EARF6
SCHEMBL20914105 0.89 PLAT (0.42) PLATHSD11B1POLBKDM4EARF6
SCHEMBL20931237 0.86 PLAT (0.36) PLATHSD11B1POLBKDM4EARF6
SCHEMBL20914421 0.86 PLAT (0.36) PLATPOLBKDM4EARF6ALDH1A1
SCHEMBL20913972 0.86 PLAT (0.42) PLATHSD11B1POLBKDM4EARF6
SCHEMBL20914350 0.85 PLAT (0.38) PLATHSD11B1POLBKDM4EARF6
SCHEMBL20914301 0.85 PLAT (0.38) PLATHSD11B1POLBKDM4EARF6
SCHEMBL20914368 0.85 PLAT (0.38) PLATHSD11B1POLBKDM4EARF6
SCHEMBL20914226 0.85 PLAT (0.47) PLAT
SCHEMBL20914147 0.85 PLAT (0.38) PLATPOLBKDM4EARF6HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 PLAT 1323/4885HSD11B1 3808/4885POLB 4311/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 PLAT 1323/4885HSD11B1 3808/4885POLB 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback